Maintenance immunotherapy fails to improve survival in extensive small cell lung cancer
(European Society for Medical Oncology) Maintenance immunotherapy fails to improve survival in extensive-stage small cell lung cancer (SCLC), according to late-breaking results from the CheckMate 451 study to be presented today at the European Lung Cancer Congress (ELCC) 2019. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 11, 2019 Category: Cancer & Oncology Source Type: news

AACR: Pembrolizumab Beneficial for Advanced Small Cell Lung Cancer
Antitumor activity promising; objective response rate 19.3 percent for patients with incurable, advanced SCLC (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 2, 2019 Category: Cancer & Oncology Tags: Oncology, Pulmonology, Conference News, Source Type: news

AACR: Pembrolizumab Beneficial for Advanced Small Cell Lung Cancer
TUESDAY, April 2, 2019 -- For patients with advanced small cell lung cancer (SCLC), pembrolizumab shows antitumor activity with durable responses, according to a study presented at the annual meeting of the American Association for Cancer Research,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 2, 2019 Category: Pharmaceuticals Source Type: news

Data from two KEYNOTE trials show pembrolizumab benefited patients with advanced SCLC
(American Association for Cancer Research) The anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) showed promising antitumor activity with durable responses in patients with pretreated, advanced small cell lung cancer (SCLC), according to results from a pooled analysis of the two clinical trials, the phase 1b KEYNOTE-028 and the phase II KEYNOTE-158, presented at the AACR Annual Meeting 2019, March 29-April 3. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2019 Category: Cancer & Oncology Source Type: news

Focus on immunotherapy and patient perspective at IASLC 2019 Small Cell Lung Cancer Meeting
(International Association for the Study of Lung Cancer) While non-small cell lung cancer (NSCLC) is the more common form of lung cancer and attracts the lion's share of the research funding, recent developments in small cell lung cancer may be shifting that slightly. In order to capitalize on these recent developments, researchers who focus on small cell lung cancer (SCLC) will gather in New York City at Memorial Sloan Kettering Cancer April 3-5, 2019, for the IASLC 2019 Small Cell Lung Cancer Meeting. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 29, 2019 Category: International Medicine & Public Health Source Type: news

Lung cancer patient channels diagnosis into lifetime activism
(International Association for the Study of Lung Cancer) The Third Biennial IASLC-sponsored Small Cell Lung Cancer Workshop will be held at Memorial Sloan Kettering Cancer Center in New York City, April 3-5, 2019, and will focus on preclinical and clinical advances in small cell lung cancer (SCLC) research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 21, 2019 Category: Cancer & Oncology Source Type: news

FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: World Pharma News)
Source: World Pharma News - March 20, 2019 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Tecentriq Approved for Small Cell Lung Cancer
TUESDAY, March 19, 2019 -- Tecentriq (atezolizumab) has been approved by the U.S. Food and Drug Administration to treat adults with extensive-stage small cell lung cancer (ES-SCLC). The drug has been approved as a first-line treatment for the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 19, 2019 Category: General Medicine Source Type: news

FDA approves Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Media News)
Source: Roche Media News - March 19, 2019 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - March 19, 2019 Category: Pharmaceuticals Source Type: news

Prophylactic cranial irradiation: Improvements for advanced NSCLC
(NRG Oncology) Prophylactic cranial irradiation (PCI), a technique used to prevent the clinical development of brain metastases, is established as a standard approach for many patients with small cell lung cancer (SCLC) after initial therapy. While studies established that PCI decreases the incidence of brain metastases for patients with locally advanced non-small cell lung cancer (LA-NSCLC), there is no established indication for its use for such NSCLC patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 18, 2019 Category: Cancer & Oncology Source Type: news

Sharp Drop in PCI Use for Extensive-Stage SCLC
(MedPage Today) -- Survey shows rapid adoption of new data, shift toward MRI surveillance (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 13, 2019 Category: American Health Source Type: news

Sharp Drop in Prophylactic Brain Irradiation in SCLC
(MedPage Today) -- Survey shows rapid adoption of new data, shift toward MRI surveillance (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 13, 2019 Category: American Health Source Type: news

Researchers develop human cell-based model to study small cell lung cancer
(Rockefeller University Press) Researchers from Weill Cornell Medicine have used human embryonic stem cells to create a new model system that allows them to study the initiation and progression of small cell lung cancer (SCLC). The study, which will be published February 8, 2019 in the Journal of Experimental Medicine, reveals the distinct roles played by two critical tumor suppressor genes that are commonly mutated in these highly lethal cancers. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 8, 2019 Category: Biology Source Type: news

Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition
Small cell lung cancer (SCLC) is a recalcitrant, aggressive neuroendocrine-type cancer for which little change to first-line standard-of-care treatment has occurred within the last few decades. Unlike nonsmall cell lung cancer (NSCLC), SCLC harbors few actionable mutations for therapeutic intervention. Lysine-specific histone demethylase 1A (LSD1 also known as KDM1A) inhibitors were previously shown to have selective activity in SCLC models, but the underlying mechanism was elusive. Here, we found that exposure to the selective LSD1 inhibitor ORY-1001 activated the NOTCH pathway, resulting in the suppression of the transcr...
Source: Signal Transduction Knowledge Environment - February 5, 2019 Category: Science Authors: Augert, A., Eastwood, E., Ibrahim, A. H., Wu, N., Grunblatt, E., Basom, R., Liggitt, D., Eaton, K. D., Martins, R., Poirier, J. T., Rudin, C. M., Milletti, F., Cheng, W.-Y., Mack, F., MacPherson, D. Tags: STKE Research Articles Source Type: news

Patients With Lower-Stage Small-Cell Lung Cancer Do Better Patients With Lower-Stage Small-Cell Lung Cancer Do Better
Patients with stage I to II small-cell lung cancer (SCLC) treated with chemoradiotherapy have better outcome than those with stage III disease, according to a secondary analysis of a randomized clinical trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

FDA grants priority review to Roche's Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC). (Source: World Pharma News)
Source: World Pharma News - December 6, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Roche's Tecentriq wins speedy U.S. review in small cell lung cancer
Roche's Tecentriq immunotherapy with chemotherapy won priority review in the United States for the initial treatment of extensive-stage small cell lung cancer (SCLC), the company said, setting up possible approval by March 18. (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA grants priority review to Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC). (Source: Roche Media News)
Source: Roche Media News - December 5, 2018 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - December 5, 2018 Category: Pharmaceuticals Source Type: news

Age Just a Number for Older, Fit Limited-Stage SCLC Patients
(MedPage Today) -- Standard chemoradiotherapy proved just as effective compared with younger patients (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 9, 2018 Category: Hematology Source Type: news

Concurrent chemo-radiotherapy should be a treatment option for elderly patients with LS-S
(International Association for the Study of Lung Cancer) Elderly patients with limited-stage small cell lung cancer (LS-SCLC) showed similar survival and toxicity compared to their younger counterparts when treated with concurrent chemo-radiotherapy. Concurrent chemo-radiotherapy should be a treatment option for fit patients aged 70 years or older. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 1, 2018 Category: Cancer & Oncology Source Type: news

Nanopore technology with DNA computing easily detects microRNA patterns of lung cancer
(Tokyo University of Agriculture and Technology) Researchers at Tokyo University of Agriculture and Technology (TUAT) have developed a simple technique that allows detection of two independent microRNAs as an early diagnosis marker of Small Cell Lung Cancer (SCLC) , which is very aggressive. In this technique, they combined nanopore and DNA computing technologies as rapid and label-free detection. This method, therefore, could help to identify SCLC in the early stage. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 5, 2018 Category: Cancer & Oncology Source Type: news

Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage
The use of potent therapies inhibiting critical oncogenic pathways active in epithelial cancers has led to multiple resistance mechanisms, including the development of highly aggressive, small cell neuroendocrine carcinoma (SCNC). SCNC patients have a dismal prognosis due in part to a limited understanding of the molecular mechanisms driving this malignancy and the lack of effective treatments. Here, we demonstrate that a common set of defined oncogenic drivers reproducibly reprograms normal human prostate and lung epithelial cells to small cell prostate cancer (SCPC) and small cell lung cancer (SCLC), respectively. We ide...
Source: ScienceNOW - October 4, 2018 Category: Science Authors: Park, J. W., Lee, J. K., Sheu, K. M., Wang, L., Balanis, N. G., Nguyen, K., Smith, B. A., Cheng, C., Tsai, B. L., Cheng, D., Huang, J., Kurdistani, S. K., Graeber, T. G., Witte, O. N. Tags: Medicine, Diseases reports Source Type: news

Roche ’s Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer
Roche today announced positive results from the Phase III IMpower133 study of Tecentriq ® (atezolizumab) plus carboplatin and etoposide (chemotherapy) for the initial (first-line) treatment of people with previously-untreated extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Media News)
Source: Roche Media News - September 25, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer
Roche today announced positive results from the Phase III IMpower133 study of Tecentriq ® (atezolizumab) plus carboplatin and etoposide (chemotherapy) for the initial (first-line) treatment of people with previously-untreated extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - September 25, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves Nivolumab (Opdivo) for Small Cell Lung Cancer FDA Approves Nivolumab (Opdivo) for Small Cell Lung Cancer
The new approval is accelerated and is therefore conditional upon further proof of efficacy, but the checkpoint inhibitor becomes the first approved option in advanced SCLC in a long time.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 17, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

BMS gets FDA ok for first new SCLC med in 20 years
Bristol-Myers Squibb announced that the U.S. FDA has approved Opdivo as a treatment for certain patients with previously treated small cell lung cancer. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 17, 2018 Category: Pharmaceuticals Source Type: news

Researchers discover new vulnerability in deadly form of lung cancer
(UT Southwestern Medical Center) Researchers at the Children's Medical Center Research Institute at UT Southwestern (CRI) have discovered a new metabolic vulnerability in small cell lung cancer (SCLC) that can be targeted by existing drug therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 3, 2018 Category: Cancer & Oncology Source Type: news

Researchers discover a new type of lung cancer
(Cold Spring Harbor Laboratory) Researchers have discovered a new kind of small-cell lung cancer (SCLC). The discovery paves the way for developing personalized medicine approaches to target this previously unnoticed form of the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 25, 2018 Category: Cancer & Oncology Source Type: news

PARP Inhibitor Active in SCLC Subgroup
(MedPage Today) -- Better OS seen among those expressing marker of DNA damage (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 23, 2018 Category: Hematology Source Type: news

PARP inhibitor improves overall response rates in small cell lung cancer patients
(University of Texas M. D. Anderson Cancer Center) In a randomized, Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, adding the PARP inhibitor veliparib to a standard chemotherapy agent improved overall response rates (ORR) in patients with small cell lung cancer (SCLC). Researchers also identified a select group of patients -- those whose tumors expressed SLFN11 -- who also saw a progression-free survival (PFS) and overall survival (OS) benefit, suggesting a promising biomarker for the PARP-inhibitor sensitivity in SCLC. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 11, 2018 Category: International Medicine & Public Health Source Type: news

Evolving Use of ICIs and Targeted Tx in NSCLC and SCLC
In this video,Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents. (Source: CancerNetwork)
Source: CancerNetwork - June 9, 2018 Category: Cancer & Oncology Authors: Apar Kishor Ganti, MD, MS Source Type: news

Targeting DNA Repair in SCLC and the Biomarker Landscape Targeting DNA Repair in SCLC and the Biomarker Landscape
Areas of investigation for SCLC include identification of predictive biomarkers, effective combinations to overcome resistance, and strategies for immunotherapy.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

New liquid biopsy-based cancer model reveals data on deadly lung cancer
(University of Texas M. D. Anderson Cancer Center) Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes. Treatment has changed little for decades, but a study at The University of Texas MD Anderson Cancer Center offers a potential explanation for why the disease becomes chemoresistant, and a possible avenue to explore new diagnostic approaches. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 15, 2018 Category: Cancer & Oncology Source Type: news

Current Standards for Clinical Management of SCLC Current Standards for Clinical Management of SCLC
Review the latest on diagnosis, staging, and management of SCLC.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 15, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

PharmaMar's lurbinectedin ATLANTIS trial in SCLC will be an oral presentation
(Pharmamar) PharmaMar's lurbinectedin will have an oral presentation on small-cell lung cancer at the 18th annual meeting on Targeted Therapies in Lung Cancer that is organized by the International Association for the Study of Lung Cancer (IASLC), to be held in Santa Monica Feb. 21-24. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 20, 2018 Category: Cancer & Oncology Source Type: news

Pazopanib Improves PFS in Extensive-Disease SCLC, But Adds Toxicity
Maintenance therapy with pazopanib significantly prolonged progression-free survival in patients with extensive-disease small-cell lung cancer, but with toxicity. (Source: CancerNetwork)
Source: CancerNetwork - February 16, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news

Clinical Utility of CTCs in Patients With SCLC Clinical Utility of CTCs in Patients With SCLC
Learn how CTCs can be diagnostic, prognostic, and predictive biomarkers in SCLC.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 10, 2018 Category: Consumer Health News Tags: None Journal Article Source Type: news

Many SCLC Patients Not Receiving Standard of Care Many SCLC Patients Not Receiving Standard of Care
A large proportion of limited-stage small cell lung cancer (SCLC) patients are not receiving standard-of-care treatment. One barrier appears to be coverage with Medicare/Medicaid.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 9, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

One in Five Limited-Stage SCLC Patients Get No Treatment (CME/CE)
(MedPage Today) -- Federally insured patients less likely to get radiation therapy (Source: MedPage Today Radiology)
Source: MedPage Today Radiology - January 5, 2018 Category: Radiology Source Type: news

Small-cell lung cancer patients face barriers to receiving standard-of-care treatment
(University of Texas M. D. Anderson Cancer Center) Despite decades of clinical research establishing chemotherapy with thoracic radiation as the standard-of-care for the initial management of non-metastatic small-cell lung cancer (SCLC), a large percentage of US patients do not receive these treatments and in turn have lower overall survival, according to research from The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 4, 2018 Category: International Medicine & Public Health Source Type: news

Biopsy specimen found to be reliable for evaluating DLL3 expression in small cell lung cancer
(International Association for the Study of Lung Cancer) Small cell lung cancer (SCLC) biopsy specimen was found to be reliable material for evaluating DLL3 expression; high levels of DLL3 in SCLC are correlated with poor survival trends. Dr. Li-Xu Yan of Guangdong General Hospital and Guangdong Academy of Medical Sciences in China presented her findings from this study today at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 16, 2017 Category: Cancer & Oncology Source Type: news

New data on PM1183 sees a response rate of 36 percent as single agent in patients with SCLC
(Pharmamar) Up to today, there is only one approved therapy, topotecan, in relapsed disease, that offers a response rate of between 17 percent and 24 percent. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 12, 2017 Category: Cancer & Oncology Source Type: news

Anti-PD 1 Drug Active in Extensive SCLC (CME/CE)
(MedPage Today) -- Pembrolizumab provided 33% response rate in poor-prognosis disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 24, 2017 Category: Hematology Source Type: news

Study Finds That Proton-Beam Therapy is Safe for Treating an Aggressive Type of Lung Cancer
Proton-beam radiotherapy is safe and appears to be effective in treating some cases of small cell lung cancer (SCLC), an aggressive cancer that accounts for about 10 to 15 percent of all lung cancers, according to a new study published online in the journal Cancer. (Source: University of Maryland School of Medicine News Headlines)
Source: University of Maryland School of Medicine News Headlines - August 10, 2017 Category: Universities & Medical Training Source Type: news

Once-Daily RT Fails to Improve Over Standard in Limited-Stage SCLC
Once-daily RT given concurrently with chemotherapy showed no difference in survival compared with the twice-daily standard in small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news

Proton-Beam Therapy in Limited-Stage SCLC Shows Promising Efficacy
Proton-beam therapy was found to be safe for patients with limited-stage small-cell lung cancer in the first prospective registry study of the therapy, with only a small number of high-grade toxicities. (Source: CancerNetwork)
Source: CancerNetwork - July 10, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Radiation Oncology Source Type: news

Adding Palifosfamide in Extensive-Stage SCLC Did Not Increase Survival
Adding palifosfamide to carboplatin and etoposide failed to improve survival over the latter two agents alone in patients with extensive-stage small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 19, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news

Nivolumab Alone or With Ipilimumab Produced Durable Response in SCLC
Treatment with nivolumab alone and in combination with ipilimumab resulted in durable responses in patients with previously treated small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 16, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Lung Cancer News Source Type: news